Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: Methods and data comparison results

Hemodialysis International

Volumn 12, Issue 4, 2008, Pages 480-491

  Peter, Wendy L ^a,b   Liu, Jiannong ^b   Weinhandl, Eric D ^b   Fan, Qiao ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Calcium based phosphate binder; Hemodialysis; Morbidity; Mortality; Sevelamer

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; SEVELAMER; TUMS;

ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE FACILITY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MEDICAID; MEDICARE; MORBIDITY; MORTALITY; PATIENT IDENTIFICATION; TREATMENT OUTCOME;

ADULT; AGED; CALCIUM COMPOUNDS; CHELATING AGENTS; DATABASES, FACTUAL; HOSPITALIZATION; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MEDICAID; MEDICARE; MIDDLE AGED; MORBIDITY; PHOSPHATES; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; UNITED STATES;

EID: 53549118305     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00312.x     Document Type: Article

References (12)

1. United States Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005.
2. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347: 2010-2019.
3. Besarab A, Bolton JK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590.
4. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.
5. St Peter W, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008; 51: 445-454.
6. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130-1137.
7. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: Time for a reassessment? J Am Coll Cardiol. 1999; 34: 618-620.
8. Diaz LA, Brunken RC, Blackstone EH, et al. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary artery disease. J Am Coll Cardiol. 2001; 37: 1558-1564.
9. Cardiology Division-Duke University Medical Center. Clinical Trials information page. Available from: http://dukecardiology.duke.edu/ clinicalTrialList.asp?divisionID=39. 2006 (accessed date: July 26, 2006).
10. United States Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
11. Marks AS, Lee DW, Slezak J, Berger J, Patel H, Johnson KE. Agreement between insurance claim and self-reported hospital and emergency room utilization data among persons with diabetes. Dis Manage. 2003; 6: 199-205.
12. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical research. J Clin Oncol. 2003; 21: 4145-4150.